How much revenue does Gujarat Terce Laboratories make?

Gujarat Terce Laboratories reported 501.95 million INR in revenue for fiscal year 2025, up 4.6% from 479.75 million INR in fiscal year 2024. In Q3 2026 revenue was 122.94 million INR.

What companies are similar to Gujarat Terce Laboratories?

Listed companies of a similar size in the same industry (multi-therapeutic drug manufacturing) include Kabra Drugs Limited (KABRADG.BO), Vista Pharmaceuticals Limited (VISTAPH.BO), Bharat Immunologicals & Biologicals Corporation Limited (BIBCL.BO), Chandra Bhagat Pharma Ltd (CBPL.BO).

Gujarat Terce Laboratories Limited (GUJTERC.BO) Stock

About Gujarat Terce Laboratories Limited

Gujarat Terce Laboratories Limited develops, manufactures, markets, and distributes medicines and healthcare products in India and internationally. The company offers generic pharmaceutical for therapeutic areas, such as antibiotics, respiratory, nutraceuticals, gastrology, gynecology, pain therapy, and ayurvedic. It provides tablets, capsules, oral liquids, ointments, and injections under the Aco...

At a glance

Gujarat Terce Laboratories reported revenue of 501.95 million INR for fiscal year 2025, up 4.6% from fiscal year 2024, and net income of -9.79 million INR. In Q3 2026 (the quarter ended December 31, 2025) revenue was 122.94 million INR, down 3.1% from a year before.

Figures from company filings; latest fiscal year ended March 31, 2025.

No profile data available.

Disclaimer: This analysis is for informational and educational purposes only and does not constitute financial, investment, tax, or legal advice. Data may be incomplete, delayed, or contain inaccuracies. Consult with a qualified financial advisor before making any investment decisions.